Eli Lilly beats Q3 2026 earnings and lifts full‑year revenue outlook while trimming EPS guidance
Eli Lilly reported third‑quarter 2026 revenue of $24.4 billion, up 39 % year‑over‑year, and earnings per share of $7.22 on a GAAP basis and $7.48 on a non‑GAAP basis. The company raised its full‑year revenue guidance to $91 billion‑$92 billion, up from $85 billion‑$87 billion, but lowered its adjusted EPS outlook to $35‑$36 per share, down from $35.5‑$36.5, citing $4.57 per share of acquisition‑related IPR&D charges. Strong sales of the weight‑loss drugs Mounjaro ($10.72 billion) and Zepbound ($5.35 billion) drove the results, while the new obesity pill Foundayo generated $184 million.

